Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BV100 Alone and With Itraconazole
NCT05684718Phase 1Completed
- Sponsor
- BioVersys AG
- Start
- Feb 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BV100 in Acinetobacter baumannii infection, sponsored by BioVersys AG. Primary endpoints: Pharmacokinetics of intravenous rifabutin (AUC, Cmax) and Pharmacokinetics of intravenous 25-O-deacetyl-rifabutin. Started Feb 2023; status: completed.
02
Drugs
BV100
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT05684718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684718.